DMPA + Testosterone
Depot Medroxyprogesterone Acetate + Testosterone
- User: Male
- Hormonal: Hormonal
-
Delivery type:
- Multiple
- Injectable
- Subdermal
-
Intended Duration:
- Short-Acting
- Development Stage: Phase I
- Developer(s)/researcher(s): ANZAC Research Institute
Details
- API: Medroxyprogesterone Acetate, Testosterone
- Target: Progesterone Receptor, Androgen Receptor
-
Mechanism of Action:
- Reduced Sperm Production
- Inactive Materials: Undetermined
- Regimen: Testosterone every 4 months, DMPA every 3 months
- MPT: Not Potential MPT
Product Status
Not listed as a current project for ANZAC, no further activity from other researchers
History
Advanced to clinical research. 55 healthy men in stable fertile relationships participated in a proof of principle study, with a 12-month contraceptive efficacy period. Sperm density fell rapidly, so 94% of men entered the efficacy phase by 3 months, with only 2 of 55 (3.6%) men not sufficiently suppressed to enter efficacy. No pregnancies occurred in 35.5 person-years. Recovery was complete with medians of 3.6 months to sperm reappearance and 5 months to 20 million sperm/ml.